News · 26 weeks72+200%
2026-03-012026-08-23
Mix3190d
- Insider9(29%)
- Other8(26%)
- Analyst8(26%)
- SEC Filings3(10%)
- Earnings2(6%)
- Leadership1(3%)
Latest news
25 items- INSIDERPresident and CEO Mcevoy Ashley bought $162,217 worth of shares (1,100 units at $147.47), increasing direct ownership by 5% to 23,731 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Insulet CorporationSCHEDULE 13G/A - INSULET CORP (0001145197) (Subject)
- ANALYSTInsulet downgraded by Truist with a new price targetTruist downgraded Insulet from Buy to Hold and set a new price target of $153.00
- ANALYSTInsulet downgraded by Wells Fargo with a new price targetWells Fargo downgraded Insulet from Overweight to Equal Weight and set a new price target of $144.00
- ANALYSTInsulet downgraded by Analyst with a new price targetAnalyst downgraded Insulet from Overweight to Neutral and set a new price target of $152.00
- ANALYSTInsulet downgraded by BTIG ResearchBTIG Research downgraded Insulet from Buy to Neutral
- ANALYSTInsulet downgraded by Leerink Partners with a new price targetLeerink Partners downgraded Insulet from Outperform to Market Perform and set a new price target of $145.00
- SECSEC Form 10-Q filed by Insulet Corporation10-Q - INSULET CORP (0001145197) (Filer)
- ANALYSTInsulet downgraded by OppenheimerOppenheimer downgraded Insulet from Outperform to Perform
- SECInsulet Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INSULET CORP (0001145197) (Filer)
- PRInsulet Reports Second Quarter 2026 ResultsSecond Quarter Revenue of $802 million, Increase of 23.5% (22.7% in Constant Currency1) Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended June 30, 2026. Second Quarter Financial Highlights: Revenue of $801.7 million, up 23.5%, or 22.7% in constant currency, and exceeded the high end of the Company’s guidance range of 20% - 22% at constant currency rates Total Omnipod revenue of $795.9 million, rose 24.6%, or 23.8% in constant currency U.S. Omnipod revenue of $544.1 million, increased 20.1% International Omnipod re
- INSIDERSVP, Chief HR Officer Davis Lisa Blair covered exercise/tax liability with 244 shares, decreasing direct ownership by 5% to 4,453 units (SEC Form 4) (withholding tax)4 - INSULET CORP (0001145197) (Issuer)
- ANALYSTUBS resumed coverage on Insulet with a new price targetUBS resumed coverage of Insulet with a rating of Neutral and set a new price target of $174.00
- PRInsulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila MossThe partnership introduces The Mind in Range Collection, a set of tailored mindfulness resources available at no cost to the diabetes community, including a meditation series, a breathing exercise, and a new Calm Sleep Story narrated by Omnipod® user and fashion model Lila Moss, designed to help listeners unwind and feel supported With 359 million people worldwide living with an anxiety disorder1, and people with diabetes being 20% more likely to develop anxiety2, this initiative reinforces Insulet’s commitment to whole-person care and positions mental health as essential to diabetes management The integrated content collaboration is the first-of-its-kind between Calm and a MedTe
- INSIDERAmendment: Director Huffines Robert Luther was granted 151 shares, increasing direct ownership by 7% to 2,449 units (SEC Form 4)4/A - INSULET CORP (0001145197) (Issuer)
- PRInsulet Accelerates Global Growth with Launch of Omnipod® 5 and Omnipod Discover™ in Spain, Expanding Access to Tubeless Diabetes TechnologyOmnipod 5 Automated Insulin Delivery System now available in 20 countries worldwide New web-based data platform Omnipod Discover simplifies diabetes insights for users, caregivers, and healthcare professionals Omnipod 5 launch in Spain is compatible with Abbott and Dexcom continuous glucose monitoring systems Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System and its proprietary data management system Omnipod Discover™ in Spain, the Company’s newest European market. Spain is the 26th country whe
- INSIDERDirector Mazelsky Jonathan Jay was granted 1,355 shares (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- INSIDERNew insider Mazelsky Jonathan Jay claimed no ownership of stock in the company (SEC Form 3)3 - INSULET CORP (0001145197) (Issuer)
- INSIDERDirector Huffines Robert Luther was granted 144 shares, increasing direct ownership by 6% to 2,442 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- PRInsulet to Announce Second Quarter 2026 Financial Results on August 5, 2026Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2026 on Wednesday, August 5, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or
- SECInsulet Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - INSULET CORP (0001145197) (Filer)
- PRInsulet Announces Appointment of Jonathan J. Mazelsky to its Board of DirectorsInsulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Jonathan ("Jay") Mazelsky to the Company’s Board of Directors, effective July 1, 2026. Mr. Mazelsky joins the Board as an independent director. "We are pleased to welcome Jay to Insulet’s Board of Directors," said President and CEO Ashley McEvoy. "Jay has a strong track record of translating science into solutions to drive growth and create significant and enduring shareholder value. His background and expertise will be integral as Insulet continues to expand access and further strengthen Omnipod’s leaders
- ANALYSTDeutsche Bank initiated coverage on Insulet with a new price targetDeutsche Bank initiated coverage of Insulet with a rating of Buy and set a new price target of $190.00
- PRInsulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to CareSTRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not only confirm the impact of Insulet's technology today—it also fuels
- INSIDERDirector Stonesifer Timothy C. bought $400,393 worth of shares (2,790 units at $143.51), increasing direct ownership by 45% to 9,041 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
PODD FAQ
7 questionsWhat does Insulet Corporation do?
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.Where does PODD stock trade?
Insulet Corporation (PODD) is listed on NASDAQ.What sector and industry is PODD in?
Insulet Corporation operates in the Health Care sector, Medical/Dental Instruments industry.When did Insulet Corporation go public?
Insulet Corporation (PODD) completed its IPO in 2007.What are analysts saying about PODD?
Insulet Corporation has had 8 recent analyst actions on file. The most recent action was from Truist: Hold on 2026-08-06.What companies are similar to PODD?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare PODD side-by-side with any of them on Quantisnow.How can I track PODD on Quantisnow?
Quantisnow aggregates Insulet Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PODD to receive live email and push alerts on every new disclosure.